Updates are available Correction dated 2022-04-01
Click to view Correction: https://doi.org/10.1038/s41467-022-29467-2
-
Authors
Gannon, Hugh S.
Zou, Tao
Kiessling, Michael K.
Gao, Galen F. https://orcid.org/0000-0003-3143-9270
Cai, Diana
Choi, Peter S.
Ivan, Alexandru P. https://orcid.org/0000-0001-7925-0253
Buchumenski, Ilana
Berger, Ashton C.
Goldstein, Jonathan T.
Cherniack, Andrew D. https://orcid.org/0000-0003-0470-0111
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
Tsherniak, Aviad https://orcid.org/0000-0002-3797-1877
Levanon, Erez Y. https://orcid.org/0000-0002-3641-4198
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Meyerson, Matthew https://orcid.org/0000-0002-9133-8108
- License Information
-
More Information
Article History
Received: 18 October 2018
Accepted: 15 November 2018
First Online: 21 December 2018
Change Date: 1 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-29467-2
Competing interests
: H.S.G. is now an employee of KSQ Therapeutics, Inc. in Cambridge, MA. W.C.H. is a founder of and consultant for KSQ Therapeutics, Inc. in Cambridge, MA. M.M. receives research funding from Bayer; had equity interest in Foundation Medicine (former, partially sold to Roche); had a consulting or advisory role with Foundation Medicine (former) and OrigiMed; and received patent royalties on intellectual property from Dana-Farber Cancer Institute licensed to LabCorp. M.M. and H.S.G. are inventors on a patent application for the use of ADAR1 inhibitors in cancer treatment. The remaining authors declare no competing interests.
